Literature DB >> 25385797

Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.

Z Zhang1, X Chen2, L D Hernandez1, P Lipari1, A Flattery1, S-C Chen1, S Kramer1, J D Polishook1, F Racine1, H Cape1, C P Kelly2, A G Therien3.   

Abstract

The exotoxins TcdA and TcdB are the major virulence factors of Clostridium difficile. Circulating neutralizing antitoxin antibodies are protective in C. difficile infection (CDI), as demonstrated, in part, by the protective effects of actoxumab and bezlotoxumab, which bind to and neutralize TcdA and TcdB, respectively. The question of how systemic IgG antibodies neutralize toxins in the gut lumen remains unresolved, although it has been suggested that the Fc receptor FcRn may be involved in active antibody transport across the gut epithelium. In this study, we demonstrated that genetic ablation of FcRn and excess irrelevant human IgG have no impact on actoxumab-bezlotoxumab-mediated protection in murine and hamster models of CDI, suggesting that Fc-dependent transport of antibodies across the gut wall is not required for efficacy. Tissue distribution studies in hamsters suggest, rather, that the transport of antibodies depends on toxin-induced damage to the gut lining. In an in vitro two-dimensional culture system that mimics the architecture of the intestinal mucosal epithelium, toxins on the apical side of epithelial cell monolayers are neutralized by basolateral antibodies, and antibody transport across the cell layer is dramatically increased upon addition of toxin to the apical side. Similar data were obtained with F(ab')2 fragments, which lack an Fc domain, consistent with FcRn-independent paracellular, rather than transcellular, transport of antibodies. Kinetic studies show that initial damage caused by apical toxin is required for efficient neutralization by basolateral antibodies. These data may represent a general mechanism of humoral response-mediated protection against enteric pathogens.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25385797      PMCID: PMC4288887          DOI: 10.1128/IAI.02550-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria.

Authors:  Masaru Yoshida; Kanna Kobayashi; Timothy T Kuo; Lynn Bry; Jonathan N Glickman; Steven M Claypool; Arthur Kaser; Takashi Nagaishi; Darren E Higgins; Emiko Mizoguchi; Yoshio Wakatsuki; Derry C Roopenian; Atsushi Mizoguchi; Wayne I Lencer; Richard S Blumberg
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

Review 2.  Restoration of barrier function in injured intestinal mucosa.

Authors:  Anthony T Blikslager; Adam J Moeser; Jody L Gookin; Samuel L Jones; Jack Odle
Journal:  Physiol Rev       Date:  2007-04       Impact factor: 37.312

3.  Mouse relapse model of Clostridium difficile infection.

Authors:  Xingmin Sun; Haiying Wang; Yongrong Zhang; Kevin Chen; Barbara Davis; Hanping Feng
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

4.  Functional reconstitution of human FcRn in Madin-Darby canine kidney cells requires co-expressed human beta 2-microglobulin.

Authors:  Steven M Claypool; Bonny L Dickinson; Masaru Yoshida; Wayne I Lencer; Richard S Blumberg
Journal:  J Biol Chem       Date:  2002-05-22       Impact factor: 5.157

5.  Treatment with monoclonal antibodies against Clostridium difficile toxins.

Authors:  Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

6.  Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A.

Authors:  Tim Du; Michelle J Alfa
Journal:  Can J Infect Dis       Date:  2004-03

7.  Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells.

Authors:  Masaru Yoshida; Steven M Claypool; Jessica S Wagner; Emiko Mizoguchi; Atsushi Mizoguchi; Derry C Roopenian; Wayne I Lencer; Richard S Blumberg
Journal:  Immunity       Date:  2004-06       Impact factor: 31.745

8.  LRP1 is a receptor for Clostridium perfringens TpeL toxin indicating a two-receptor model of clostridial glycosylating toxins.

Authors:  Björn Schorch; Shuo Song; Ferdy R van Diemen; Hans H Bock; Petra May; Joachim Herz; Thijn R Brummelkamp; Panagiotis Papatheodorou; Klaus Aktories
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-15       Impact factor: 11.205

Review 9.  Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Authors:  Maja Rupnik; Mark H Wilcox; Dale N Gerding
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

Review 10.  Toward a structural understanding of Clostridium difficile toxins A and B.

Authors:  Rory N Pruitt; D Borden Lacy
Journal:  Front Cell Infect Microbiol       Date:  2012-03-16       Impact factor: 5.293

View more
  22 in total

1.  Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis.

Authors:  Jun Huang; Ciarán P Kelly; Kyriaki Bakirtzi; Javier A Villafuerte Gálvez; Dena Lyras; Steven J Mileto; Sarah Larcombe; Hua Xu; Xiaotong Yang; Kelsey S Shields; Weishu Zhu; Yi Zhang; Jeffrey D Goldsmith; Ishan J Patel; Joshua Hansen; Meijin Huang; Seppo Yla-Herttuala; Alan C Moss; Daniel Paredes-Sabja; Charalabos Pothoulakis; Yatrik M Shah; Jianping Wang; Xinhua Chen
Journal:  Nat Microbiol       Date:  2018-12-03       Impact factor: 17.745

2.  Bezlotoxumab.

Authors:  Danial E Baker
Journal:  Hosp Pharm       Date:  2017-03

3.  Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.

Authors:  Lorraine D Hernandez; Heather K Kroh; Edward Hsieh; Xiaoyu Yang; Maribel Beaumont; Payal R Sheth; Edward DiNunzio; Stacey A Rutherford; Melanie D Ohi; Grigori Ermakov; Li Xiao; Susan Secore; Jerzy Karczewski; Fred Racine; Todd Mayhood; Paul Fischer; Xinwei Sher; Pulkit Gupta; D Borden Lacy; Alex G Therien
Journal:  J Mol Biol       Date:  2017-02-21       Impact factor: 5.469

Review 4.  Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

5.  Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.

Authors:  Michelle Hughes; Taha Qazi; Adam Berg; Janice Weinberg; Xinhua Chen; Ciaran P Kelly; Francis A Farraye
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

6.  Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Authors:  Peter Warn; Pia Thommes; Abdul Sattar; David Corbett; Amy Flattery; Zuo Zhang; Todd Black; Lorraine D Hernandez; Alex G Therien
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

7.  Treatment of Clostridium difficile Infection with a Small-Molecule Inhibitor of Toxin UDP-Glucose Hydrolysis Activity.

Authors:  Ilana L Stroke; Jeffrey J Letourneau; Teresa E Miller; Yan Xu; Igor Pechik; Diana R Savoly; Linh Ma; Laurie J Sturzenbecker; Joan Sabalski; Philip D Stein; Maria L Webb; David W Hilbert
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

8.  A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.

Authors:  Ka Lai Yee; Huub Jan Kleijn; Stefan Zajic; Mary Beth Dorr; Rebecca E Wrishko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-02-11       Impact factor: 2.745

9.  A probiotic yeast-based immunotherapy against Clostridioides difficile infection.

Authors:  Kevin Chen; Yixuan Zhu; Yongrong Zhang; Therwa Hamza; Hua Yu; Ashley Saint Fleur; James Galen; Zhiyong Yang; Hanping Feng
Journal:  Sci Transl Med       Date:  2020-10-28       Impact factor: 17.956

10.  The Murine Neonatal Fc Receptor Is Required for Transport of Immunization-Induced C. difficile-Specific IgG to the Gut and Protection against Disease but Does Not Affect Disease Susceptibility.

Authors:  Souwelimatou Amadou Amani; Gillian A Lang; Jimmy D Ballard; Mark L Lang
Journal:  Infect Immun       Date:  2021-06-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.